Skip to content
    GS

    Goldman Sachs Alternatives

    New York, New York, United StatesFounded 1986

    Goldman Sachs Alternatives focuses on a broad spectrum of alternative investments, including private equity (buyout, growth equity, co-investments, and secondaries), private credit, real estate, infrastructure, sustainability, and hedge funds. Their strategy involves both direct investments and partnerships with third-party asset managers to deliver diversified solutions and long-term growth for clients.

    Deal activity increased 50% year-over-year (15 deals in the last 12 months). Average disclosed round size is $359.1M (across 25 rounds with reported amounts).

    Find people at Goldman Sachs Alternatives on Goldilocks AI

    Portfolio

    29

    Fund Size

    Top Stage

    Series C

    Last 12 Mo

    15

    Team

    JR

    Josh Richardson

    Principal

    AL

    Alexander Lippert

    Gründer Und Geschäftsführer

    CW

    Colin Walsh

    Managing Director

    HP

    Harris Pollack

    Vice President

    CL

    Cedric Lucas

    Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    29 investments
    CompanyRoundAmountDate
    Schellman logoSchellmanUnknownMar 2026
    Databricks logoDatabricksGrowth$5BFeb 2026
    LearnWell logoLearnWellUnknownFeb 2026
    LearnWell logoLearnWellUnknownFeb 2026
    Fieldguide logoFieldguideSeries C$75MFeb 2026
    Redwood Materials logoRedwood MaterialsSeries E$425MJan 2026
    CCubbySeries A$63MJan 2026
    osapiens logoosapiensSeries C$100MJan 2026
    Neural Concept logoNeural ConceptSeries C$100MDec 2025
    Peek logoPeekSeries D$70MNov 2025
    Skims logoSkimsGrowth$225MNov 2025
    MoEngage logoMoEngageSeries F$100MNov 2025
    Simetrik logoSimetrikSeries B$30MJun 2025
    Bestow logoBestowSeries D$120MMay 2025
    Attovia Therapeutics logoAttovia TherapeuticsSeries C$90MApr 2025
    Fleetio logoFleetioSeries D$450MMar 2025
    Mews logoMewsSeries C$75MMar 2025
    Tines logoTinesSeries C$125MFeb 2025
    Triveni Bio Inc. logoTriveni Bio Inc.Series B$115MOct 2024
    Vicebio logoVicebioSeries B$100MSep 2024
    Vicebio logoVicebioSeries BSep 2024
    osapiens logoosapiensSeries B$110.7MJul 2024
    Vanta logoVantaSeries C$150MJul 2024
    AlphaSense logoAlphaSenseGrowth$650MJun 2024
    Attovia Therapeutics logoAttovia TherapeuticsSeries B$105MMay 2024
    Page 1 of 2

    Top Co-Investors

    venBio3 shared
    J.P. Morgan2 shared
    Medicxi2 shared
    Kinnevik2 shared
    Sanofi Ventures1 shared
    Mizuho Bank1 shared
    Springcoast Partners1 shared
    WestCap1 shared
    A91 Partners1 shared
    SignalFire1 shared

    Last updated: 12 April 2026